Wells Fargo & Company MN Sells 11,120 Shares of Immunocore Holdings plc (NASDAQ:IMCR)

Wells Fargo & Company MN lessened its position in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 13.4% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 71,935 shares of the company's stock after selling 11,120 shares during the quarter. Wells Fargo & Company MN owned approximately 0.14% of Immunocore worth $2,122,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of IMCR. Groupama Asset Managment bought a new stake in Immunocore in the fourth quarter valued at $17,700,000. Primecap Management Co. CA increased its holdings in Immunocore by 8.0% during the 4th quarter. Primecap Management Co. CA now owns 2,668,550 shares of the company's stock valued at $78,722,000 after purchasing an additional 196,530 shares in the last quarter. Principal Financial Group Inc. boosted its stake in Immunocore by 25.0% in the third quarter. Principal Financial Group Inc. now owns 546,318 shares of the company's stock worth $17,007,000 after purchasing an additional 109,206 shares in the last quarter. BIT Capital GmbH increased its stake in shares of Immunocore by 182.7% in the fourth quarter. BIT Capital GmbH now owns 67,840 shares of the company's stock valued at $2,001,000 after buying an additional 43,840 shares in the last quarter. Finally, State Street Corp raised its holdings in shares of Immunocore by 63.9% in the third quarter. State Street Corp now owns 76,671 shares of the company's stock valued at $2,387,000 after buying an additional 29,897 shares during the last quarter. 84.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Morgan Stanley reiterated an "equal weight" rating and set a $35.00 target price on shares of Immunocore in a research report on Friday, March 7th. Mizuho decreased their price objective on Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a research report on Monday, April 7th. HC Wainwright reaffirmed a "buy" rating and set a $100.00 price target on shares of Immunocore in a research note on Wednesday, March 12th. JPMorgan Chase & Co. lowered their price objective on Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a research report on Monday, April 14th. Finally, Needham & Company LLC restated a "buy" rating and set a $71.00 target price on shares of Immunocore in a research report on Thursday, April 10th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, Immunocore has a consensus rating of "Hold" and an average price target of $59.44.

Immunocore Stock Up 0.0 %

Shares of IMCR stock traded up $0.01 during trading hours on Thursday, hitting $30.11. 3,596 shares of the company were exchanged, compared to its average volume of 432,662. Immunocore Holdings plc has a 52 week low of $23.15 and a 52 week high of $62.74. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. The business has a 50 day moving average of $28.81 and a two-hundred day moving average of $30.34. The company has a market capitalization of $1.51 billion, a PE ratio of -31.69 and a beta of 0.75.

Insiders Place Their Bets

In related news, Director Bros. Advisors Lp Baker acquired 807,338 shares of the firm's stock in a transaction dated Monday, March 17th. The stock was bought at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the acquisition, the director now directly owns 2,144,060 shares of the company's stock, valued at approximately $63,721,463.20. The trade was a 60.40 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 10.40% of the company's stock.

Immunocore Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.